TriLink and Alphazyme Collaborate on New RNA Polymerase to Reduce dsRNA upto 85%

• TriLink BioTechnologies and Alphazyme launched CleanScribe™ RNA Polymerase, reducing double-stranded RNA (dsRNA) in mRNA production by up to 85%.

• The enzyme aims to support safer, more potent mRNA therapeutics by reducing dsRNA, a byproduct that can trigger inflammatory responses.

TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to introduce CleanScribe™ RNA Polymerase. This novel enzyme reduces the formation of double-stranded RNA (dsRNA) by up to 85% during in vitro transcription (IVT) for mRNA production, a key step towards safer and more potent mRNA therapeutics.

The enzyme catalyses the transcription of recombinant genes while minimising dsRNA, a byproduct known to trigger unwanted inflammatory responses in cells. By cutting dsRNA significantly, CleanScribe™ offers a more reliable option for drug developers working on mRNA-based treatments, including therapeutics, vaccines, and diagnostics.

Justin Barbosa, Vice President and General Manager of TriLink Discovery, commented, “In this era of mRNA-based medicine, drug developers must streamline their supply chain to remain agile and keep up with demand.” He emphasised the importance of integrating high-performance IVT enzymes like CleanScribe™ in mRNA manufacturing.

CleanScribe™ is designed for easy incorporation into existing IVT protocols without extensive optimisation, making it accessible for researchers. Chad Decker, VP and General Manager at Alphazyme, stated, “You can’t produce high-quality mRNA-based therapeutics without high-quality raw material, which is why the potential impact of this IVT enzyme on the field is so exciting.”